Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KPTI | US
0.03
3.85%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
13/09/2024
0.76
0.73
0.77
0.73
Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company discovers develops and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers develops and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies including multiple myeloma endometrial cancer myelofibrosis and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms as well as verdinexor KPT-9274 and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor eltanexor and KPT-9274 for the treatment and/or prevention of human oncology indications as well as verdinexor for the diagnosis treatment and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton Massachusetts.
View LessStrength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
86.0%1 month
65.5%3 months
73.4%6 months
81.0%-
-
12.05
-1.48
0.91
-1.85
0.95
-0.15
-130.61M
91.51M
91.51M
-
-65.72
-
13.90
-891.05
31.83
15.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.11
Range1M
0.16
Range3M
0.47
Rel. volume
1.34
Price X volume
494.00K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 1.98 | 81.09M | 0.51% | n/a | 41.98% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 8.15 | 80.20M | -0.12% | n/a | 3.08% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 3.09 | 79.92M | -5.50% | n/a | 0.00% |
Silver Spike Investment Corp. Common Stock | SSIC | Drug Manufacturers-Specialty & Generic | 11.38 | 70.73M | 0.00% | 12.64 | 0.00% |
DURECT Corporation | DRRX | Drug Manufacturers-Specialty & Generic | 1.51 | 49.72M | -1.95% | n/a | 318.92% |
Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.097 | 48.88M | -7.97% | n/a | 0.00% |
SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 1.46 | 48.08M | 8.96% | n/a | 25.73% |
Eagle Pharmaceuticals Inc | EGRX | Drug Manufacturers-Specialty & Generic | 4.31 | 46.18M | 12.53% | 5.07 | 27.85% |
Cannex Capital Holdings Inc | ARRXF | Drug Manufacturers-Specialty & Generic | 0.1541 | 39.36M | 31.60% | n/a | 0.50% |
Qilian International Holding Group Limited | QLI | Drug Manufacturers-Specialty & Generic | 6.48 | 35.96M | 3.02% | n/a | 1.35% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Culp Inc | CULP | Textile Manufacturing | 5.72 | 75.14M | -2.56% | n/a | 11.29% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 2.965 | 26.61M | -13.30% | n/a | 54.96% |
ILAG | ILAG | Building Products & Equipment | 1.1699 | 20.96M | -0.85% | n/a | 5.48% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.7456 | 10.41M | 7.76% | n/a | 422.08% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.07 | 10.31M | 35.44% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.5337 | 4.94M | 18.60% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.31 | 3.62M | 1.55% | n/a | 9.62% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2475 | 3.40M | 15.12% | n/a | 0.97% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0133 | 1.20M | 10.83% | n/a | -37.05% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.7797 | 447.17K | -48.02% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.85 | - | Cheaper |
Ent. to Revenue | 0.95 | - | Cheaper |
PE Ratio | - | 29.14 | - |
Price to Book | 12.05 | 12.81 | Par |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 73.37 | - | Par |
Debt to Equity | -1.48 | -0.93 | Cheaper |
Debt to Assets | 0.91 | 0.45 | Expensive |
Market Cap | 91.51M | - | Emerging |